Download Einstein Technologies (Infectious Disease)

Einstein Technologies (Infectious Disease)
Senior Einstein
Investigator
Link to NonProvisional
Patent
Application
C-740
The present invention provides methods for determining a putative
Methods for determining
antibacterial, the methods comprising determining whether the
chemotherapeutic
putative antibacterial inhibits GlgE or Rv3032. The present invention
agents targeting alpha- also provides the antibacterial, the pharmaceutical composition and William R Jacobs, Jr.
glucan pathways and
the method of making the antibacterial as well as a method of
uses thereof
treating a subject infected with a bacterial comprising administration
of the antibacterial.
US 12/925,633
C-771
Cultures and protocols
for diagnosis of toxigenic
Clostridium difficile
Disclosed are culture media, protocols and kits for diagnosis of
toxigenicClostridium difficile , where the culture medium comprises
Cooked Meat Medium with glucose; yeast extract; taurocholate;
cycloserine; and cefoxitin.
Paul Riska
US 13/068,682
Selective betaglucuronidase inhibitors
as a treatment for side
effects of camptothecin
antineoplastic agents
Compounds, compositions and methods are provided that comprise
selective β-glucuronidase inhibitors for both aerobic and anaerobic
bacteria, especially enteric bacteria normally associated with the
gastrointestinal tract. The compounds, compositions and methods
can be for inhibiting bacterial β-glucuronidases and for improving
efficacy of camptothecin-derived antineoplastic agents or
glucuronidase-substrate agents or compounds by attenuating the
side effects caused by reactivation by bacterial β-glucuronidases of
glucuronidated metabolites of camptothecin-derived antineoplastic
agents or glucuronidase-substrate agents or compounds.
Sridhar Mani
PCT/US2010/059690
C-809
Methods and assays for
treating filoviridae
infections
Methods and assays for treating a subject with a filovirus infection
using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6,
VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE,
ARHGAP23 or FIG4. Methods for screening for an agent that treats
and/or prevents infection of a subject with a filovirus, where the
methods comprise determining whether the agent inhibits one or
more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39,
VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4,
wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6,
VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE,
ARHGAP23 or FIG4 is a candidate for treating and/or preventing an
infection with a filovirus and wherein an agent that does not inhibit
NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2,
GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating
and/or preventing an infection with a filovirus.
Kartik Chandran
PCT/US2012/022349
C-914
Methods and compositions are provided for treating HIV infection
and for inhibiting HIV infection, and for identifying purinergic
receptor antagonists or Panx 1 hemi-channel blockers useful therefor.
The invention provides a method of treating a mammalian subject
Novel cellular targets for having an HIV infection, or suspected of having been exposed to HIV,
hiv infection
comprising administering to the mammalian subject an amount of (i)
an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a
purinergic receptor, effective to inhibit (a) HIV fusion with a target
cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or
more of (a), (b) and (c).
Joan Berman
PCT/US2013/28160
Einstein
Reference
Number
C-783
C-927
C-951
Title of Patent
Application
Abstract
Mycobacterium
tuberculosis δesx-3
mutants
Isolated mutant Mycobacterium tuberculosis bacteria comprising a
deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are
provided, as well as compositions comprising such, methods of
production thereof and methods of use thereof.
Gut barrier dysfunction
treatment and
prevention
Methods are disclosed for treating and preventing gut barrier
dysfunction or an illness associated with gut barrier dysfunction in a
subject comprising administering to the subject bacterium that
produce an indole or an indole metabolite and for identifying
compounds and bacteria for use in treatment and prevention of gut
barrier dysfunction or an illness associated with gut barrier
dysfunction.
***Please note these technologies are representative of the Einstein Intellectual Property
Portfolio that are currently published patents/patent applications and available for licensing.
For non-published technologies please contact [email protected].
William R Jacobs, Jr. PCT/US2013/040559
Sridhar Mani
PCT/US2013/072709
Version March 2016
Einstein Technologies (Infectious Disease)
Einstein
Reference
Number
Title of Patent
Application
Abstract
Senior Einstein
Investigator
C-952
Method to treat or
prevent herpesvirus
infections
Link to NonProvisional
Patent
Application
Methods and compositions are provided for inhibiting or treating a
herpesvirus infection in a subject using inhibitors of mammalian Akt.
Betsy Herold
PCT/US2013/051987
Steven Anthony
Porcelli
PCT/CA2012/001095
C-989
The present disclosure pertains to antimicrobial compositions for
intravenous administration to patients who have experienced a
serious brain trauma, to reduce the risk of occurrence of post-trauma
Prophylactic
microbial infections. The antimicrobial compositions comprise an αcompositions for
galacytosylceramide compound and one or more excipients. The
management of
present disclosure also pertains to the use of α-galacytosylceramide
microbial infections in
compounds for the manufacture of antimicrobial medicaments for
patients with brain injury intravenous administration to patients with serious brain traumas.
The present disclosure also pertains to methods for the prophylactic
use of the antimicrobial compositions to reduce the risks of
occurrence of post-trauma microbial infections.
***Please note these technologies are representative of the Einstein Intellectual Property
Portfolio that are currently published patents/patent applications and available for licensing.
For non-published technologies please contact [email protected].
Version March 2016